ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Novo Nordisk’s ziltivekimab hits primary endpoint in CKD trial pharmatimes
May 18, 2021Novo Nordisk’s investigational interleukin-6 (IL-6) inhibitor ziltivekimab met the primary endpoint in a Phase II trial in people with advanced chronic kidney disease (CKD) and elevated high-sensitivity C-reactive protein (hsCRP), representing high ... -
Novo snaps up cardio-renal group Corvidia pharmatimes
June 16, 2020Novo Nordisk has signed a deal to acquire Corvidia Therapeutics, a privately held, clinical stage company with a focus on the research and development of transformative therapies for cardio-renal diseases.
Pharma Sources Insight January 2025
